Table 3.
Efficacy Endpoints
| Efficacy Endpoint | Cabozantinib | |
|---|---|---|
| N | % | |
| Best Objective Tumor Response | ||
| Stable Disease (≥6 weeks) | 7 | 54 |
| Disease progression | 4 | 31 |
| Not evaluable | 2 | 15 |
| Complete or Partial Response | 0 | 0 |
| Progression-Free Survival | ||
| ≥6 months | 3 | 23 |
| Median (95% CI), months | 3.6 (1.8, 7.9) | |
| Overall Survival | ||
| Median (95% CI), months | 8.1 (2.7, >20.1) | |